Focused On-demand Library for Transcription factor MafB

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y5Q3

UPID:

MAFB_HUMAN

Alternative names:

V-maf musculoaponeurotic fibrosarcoma oncogene homolog B

Alternative UPACC:

Q9Y5Q3; B3KNE1; Q9H1F1

Background:

Transcription factor MafB, known as V-maf musculoaponeurotic fibrosarcoma oncogene homolog B, plays a critical role in lineage-specific hematopoiesis, influencing cell fate in myeloid cells, macrophages, osteoclasts, podocytes, and islet beta cells. Its regulatory functions extend to activating insulin and glucagon promoters, with SUMO modification modulating its transcriptional activity.

Therapeutic significance:

MafB's involvement in Multicentric carpotarsal osteolysis syndrome and Duane retraction syndrome 3 highlights its potential as a therapeutic target. Understanding the role of Transcription factor MafB could open doors to potential therapeutic strategies for these conditions.